Abstract:
A MAC protocol, useful for WLANs, is provided for random access over a channel. The protocol includes three concurrent processes. The channel includes a contention subchannel and a transmission subchannel. In the contention process, all nodes use the standard RTS/CTS mechanism operated on the contention subchannel to contend for a transmission right. When one node gains the right, all the nodes store the contention result into their respective contention queue (CQ) buffers. In the transmission process, the nodes sequentially transmit their data over the transmission subchannel according to the order of the nodes stored in the CQ buffers. When one node finishes transmission, the CQ buffers are updated. The contention and transmission processes are connected by the queuing process for dynamically updating each node's CQ buffer. When OFDM is used in a random-access system, numbers of data subcarriers in both subchannels for maximizing the system throughput are given.
Abstract:
The present invention provides a compound that inhibits activity of oncogenic ROS1, a composition comprising said compound. The present invention also provides the use of said composition for treating cancer.
Abstract:
A method for scheduling dual-armed cluster tools with wafer revisiting is provided. In order to speed up start-up transient processes, the present invention adopts a program evaluation and review technique for the analysis of start-up transient processes and develops optimization algorithms for their scheduling for dual-arm cluster tools. Then, their complexity is analyzed.
Abstract:
The present invention provides an in vivo platform for identifying and determining therapeutic or prophylactic activity of test compounds in delay-type hypersensitivity (DTH) and other inflammatory or cancerous diseases mediated by activation of IKK-βC46A mutants. The in vivo platform of the present invention is a non-human transgenic mammal, e.g., a mouse model, with a site directed mutagenesis at a cysteine residue replaced by alanine in IKK-β protein kinase. The site directed mutagenesis is introduced by a specially designed targeting vector containing a transversion in exon 3 of the Ikbkb genes encoding the IKK-β. The present invention also provides methods for generating the transgenic mammal and for determining and identifying compounds that can inhibit activation of IKK-βC46A mutants.
Abstract:
The present invention provides a method for updating a mobile terminal (MT) for a mobile communication network when the MT crosses a boundary of a first location-update (LA) area. The method comprises determining a second LA to be assigned to the MT for replacing the first LA. The second LA is characterized by a LA center and a LA size, both determined by optimizing them in a sense that a mean total location-management cost is minimized without restricting the LA center to be fixed at the initial position. The initial position is defined as the location where the MT performs a latest location update at the first LA before crossing the boundary. This invention also provides schemes of partitioning the second LA into sub-paging areas for use in paging the MT when a call arrives at the network, so as to minimize the paging cost while satisfying delay requirements.
Abstract:
In semiconductor manufacturing, there are wafer fabrication processes in cluster tools that need a wafer to visit some processing steps for more than once, leading to a revisiting process. Also, wafers may be subject to wafer residency time constraints. By considering atomic layer deposition (ALD) as a typical wafer revisiting process, this invention studies the challenging scheduling problem of single-arm cluster tools for the ALD process with wafer residency time constraints. By recognizing that the key to this problem is to schedule the robot tasks, the present invention presents different robot task sequencing strategies. With these strategies for different cases, the present invention performs the schedulability analysis and derives the schedulability conditions for such tools for the first time. If schedulable, the present invention proposes scheduling algorithms to obtain an optimal schedule efficiently. Illustrative examples are given to show the application of the proposed concepts and approach.
Abstract:
The present invention discloses a method of treating Gefitinib-resistant non-small-cell lung cancer, comprising administering an effective amount of an alkaloid. A pharmaceutical composition comprising an alkaloid admixed with a pharmaceutical carrier for treating Gefitinib-resistant non-small-cell lung cancer is also disclosed therein.
Abstract:
A method of detecting an internet attack against a computing device is disclosed. The method of detecting an internet attack against a computing device comprising the steps of receiving a plurality of incoming network packets; extracting a plurality of incoming feature packets based on the plurality of incoming network packets; predicting a predicted incoming feature packet based on the plurality of incoming feature packets; obtaining a first classification data based on one of the incoming feature packets using a first classifier; obtaining a second classification data based on the predicted incoming feature packet by using a second classifier; and performing at least one remedy action if the first classification data or the second classification data identifies the internet intrusion attack; wherein each of the plurality of incoming feature packets and the predicted incoming feature packet comprise a plurality of incoming features and a plurality of predicted features respectively.
Abstract:
A method of treating a subject suffering from cancer comprising a step of administering an effective amount of a group of double-stranded RNA molecules to the subject, wherein the RNA molecule is isolated or derived from a bacteria of the genus Escherichia. A method of inhibiting growth or proliferation of cancer cells comprising a step of contacting said cells with said RNA molecule; and a pharmaceutical composition for treating cancer comprising said RNA molecule and a pharmaceutically tolerable excipient. Also a double-stranded RNA molecule and a recombinant vector comprising the double-stranded RNA molecule.
Abstract:
A compound including a structure of Formula (I) and a preparation method thereof, wherein R1 is —OH, —CH2OH, or —OCOCH3; R2, R3, and R4 are independently —H, —CH3 or —F, and at least one of R2, R3, and R4 is —F. A method for treating a subject suffering from a viral disease includes administering an effective amount of said compound or a solvate thereof to the subject.